An objective of Dr. Marc Rothenberg’s research program is to elucidate the cellular and molecular processes involved in allergic responses in the gastrointestinal tract and lung. His laboratory has developed unique antigen-induced and genetically engineered in vivo murine, and translational human ex vivo model systems, enabling him to identify key checkpoints that regulate Th2 immunity. Findings from this research have identified and elucidated the role of IL-5, the eotaxin subfamily of chemokines, IL-13, miR-21, proteases (e.g., calpain 14), anti-proteases (e.g., SPINK7) and their related signaling pathways. This work has contributed to the development of new therapeutic strategies and drugs, such as a new class of drugs based on targeting eosinophils (e.g., anti–IL-5 humanized antibodies), which are now FDA approved for clinical usage.

Anti-interleukin 5 Therapy Development

Rothenberg 2016 Cell Anti-IL-5 timeline.


Select Related Publications

Current Projects

  • Role of CDH26 in Th2 immunity
  • Immunosuppressive effects of CDH26-Fc
  • Role of epithelial innate pro-inflammatory cytokines (IL-33 and TSLP)
  • Epithelial cell responses in allergic inflammation
  • Epithelial cell developmental lineages in esophagus
  • Isolation of human esophageal epithelial progenitors and role of IL-33
  • RNA-Seq of esophageal cells, including CD3+ T cells, mast cells and epithelial cells
  • Characterization of intraepithelial lymphocytes
  • Characterization of esophageal mast cells and eosinophils
  • Role of NTRK-A and NTRK-A inhibitors in esophageal epithelial cells
  • Role of SPINK proteins and other protease inhibitors in allergic responses